| Dr Kevin Arthur Harada, MD | |
|
20 13th St W, Havre, MT 59501-5215 | |
| (406) 265-7831 | |
| (406) 262-1636 |
| Full Name | Dr Kevin Arthur Harada |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 14 Years |
| Location | 20 13th St W, Havre, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760709661 | NPI | - | NPPES |
| 925570 | Other | MT | BLUE CROSS BLUE SHIELD |
| 1760709661 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 24698 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bear Paw Hospice | Havre, MT | Hospice |
| Northern Montana Hospital | Havre, MT | Hospital |
| Benefis Hospitals Inc | Great falls, MT | Hospital |
| Northern Montana Care Center | Havre, MT | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Montana Hospital | 2264343912 | 37 |
News Archive
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
A Mayo Clinic study of people who received anesthesia for surgery after age 40 found no association between the anesthesia and development of mild cognitive impairment later in life. Mild cognitive impairment is a stage between the normal cognitive decline of aging and dementia.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Though breast cancer researchers and advocates perpetually plead for more money, the disease is, in fact, awash in it. Last year, the National Institutes of Health, the nation's top agency for health-related research, allocated $763 million to the study of breast cancer, more than double what it committed to any other cancer.
› Verified 6 days ago
| Entity Name | Northern Montana Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427059070 PECOS PAC ID: 2264343912 Enrollment ID: O20031229000278 |
News Archive
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
A Mayo Clinic study of people who received anesthesia for surgery after age 40 found no association between the anesthesia and development of mild cognitive impairment later in life. Mild cognitive impairment is a stage between the normal cognitive decline of aging and dementia.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Though breast cancer researchers and advocates perpetually plead for more money, the disease is, in fact, awash in it. Last year, the National Institutes of Health, the nation's top agency for health-related research, allocated $763 million to the study of breast cancer, more than double what it committed to any other cancer.
› Verified 6 days ago
| Entity Name | Northern Montana Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1427059070 PECOS PAC ID: 2264343912 Enrollment ID: O20230324002238 |
News Archive
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
A Mayo Clinic study of people who received anesthesia for surgery after age 40 found no association between the anesthesia and development of mild cognitive impairment later in life. Mild cognitive impairment is a stage between the normal cognitive decline of aging and dementia.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Though breast cancer researchers and advocates perpetually plead for more money, the disease is, in fact, awash in it. Last year, the National Institutes of Health, the nation's top agency for health-related research, allocated $763 million to the study of breast cancer, more than double what it committed to any other cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin Arthur Harada, MD Po Box 1231, Havre, MT 59501-1231 Ph: (406) 265-7831 | Dr Kevin Arthur Harada, MD 20 13th St W, Havre, MT 59501-5215 Ph: (406) 265-7831 |
News Archive
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
A Mayo Clinic study of people who received anesthesia for surgery after age 40 found no association between the anesthesia and development of mild cognitive impairment later in life. Mild cognitive impairment is a stage between the normal cognitive decline of aging and dementia.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Though breast cancer researchers and advocates perpetually plead for more money, the disease is, in fact, awash in it. Last year, the National Institutes of Health, the nation's top agency for health-related research, allocated $763 million to the study of breast cancer, more than double what it committed to any other cancer.
› Verified 6 days ago
Dr. Robert T Henderson, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 20 13th St, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 | |
Dr. Carolyn Susan Aks, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 13th St W, Havre, MT 59501 Phone: 406-262-6000 | |
Dr. Mark A. Ward, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 | |
Terence N. Hankins, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 |